Compare Globus Medical Inc. Class A Common Stock (GMED) vs Virtu Financial Inc. Class A Common Stock (VIRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Virtu Financial Inc. Class A Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Virtu Financial Inc. Class A Common Stock trades at $55.56 (market cap $4.94B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.1× Virtu Financial Inc. Class A Common Stock's market cap, and Virtu Financial Inc. Class A Common Stock pays a 1.72% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Virtu Financial Inc. Class A Common Stock for 6 Days on average.
| GMED | VIRT | |
|---|---|---|
Market Cap | $10.25B | $4.94B |
Volume | 1,108,124 | 1,546,091 |
Sector | Health | Financials |
52-Week High | $96.82 | $67.93 |
52-Week Low | $58.33 | $32.53 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $14.65B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VIRT trades at $55.94, down 1.46% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.29, net income margin of 13.5%, and ROE of 31.65%. Recent expansion into Saudi Exchange block trading and consistent earnings outperformance support growth prospects. Analyst consensus price target is $63.00 with mixed ratings (38% buy, 46% hold).
VIRT presents a value opportunity with attractive valuation metrics and strong profitability, though technical indicators suggest near-term pressure. The company's market-making business demonstrates resilience with improving cash flow trends. Key risks include market volatility sensitivity and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Virtu Financial Inc. Class A Common Stock
Virtu Financial provides technology-enabled market-making and execution services. Its platforms help institutional, retail, and other market participants trade across global financial markets.
Read more on VIRT →
